New combo therapy tested in battle against tough head & neck cancers
NCT ID NCT04811027
Summary
This study tested whether adding a new immunotherapy drug (eftilagimod alpha) to a standard treatment (pembrolizumab) works better for people with advanced head and neck cancer that has spread or returned. It involved 171 participants who had not yet received treatment for their advanced cancer. The goal was to see if the two-drug combination was safer and more effective at shrinking tumors and helping patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Nikolaas
Sint-Niklaas, 9100, Belgium
-
AZ Sint-Jan Brugge
Bruges, 8000, Belgium
-
Antwerp University Hospital
Edegem, 2650, Belgium
-
Arensia Exploratory Medicine Llc
Kapitanivka, AL, 08112, Ukraine
-
Centre Hospitalier Universitaire (CHU) de Liege
Liège, 4000, Belgium
-
Herlev Hospital
Herlev, 2700, Denmark
-
Hospital 12 Octubre
Madrid, 28041, Spain
-
Hospital Universitario Lucus Augusti
Lugo, 27003, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, 28034, Spain
-
Hospital de la Santa Creu i de Sant Pau
Barcelona, 08041, Spain
-
Institut Català d'Oncologia - Hospital Universitari de Girona
Girona, 17007, Spain
-
Institute of Cancer Science - Beatson West of Scotland Cancer Centre
Glasgow, 1053, United Kingdom
-
Macquarie University Hospital
Macquarie Park, New South Wales, 2109, Australia
-
Nationales Centrum für Tumorerkrankungen Heidelberg
Heidelberg, 69120, Germany
-
Nottingham University Hospitals, NHS Trust
Nottingham, NG5 1PB, United Kingdom
-
Oncology Consultants
Houston, Texas, 77030, United States
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
START Madrid (Hospital Universitario Fundación Jiménez Díaz)
Madrid, 28040, Spain
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The Oncology Institute "Prof Dr Ion Chiricuta" I.O.C.N.
Cluj-Napoca, 400015, Romania
-
University College London Hospitals NHS Foundation - The Harley Street Clinic
London, NW1 2PG, United Kingdom
-
University Hospital Essen
Essen, 45147, Germany
-
University of Alabama at Birmingham (UAB) - O'Neal Cancer Center
Birmingham, Alabama, 35249, United States
-
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, 53127, Germany
-
Universitätsklinikum Ulm
Ulm, 89075, Germany
-
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, 08035, Spain
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.